keyword
MENU ▼
Read by QxMD icon Read
search

sacubitril

keyword
https://www.readbyqxmd.com/read/29455335/evaluating-the-safety-and-tolerability-of-sacubitril-valsartan-for-hfref-managed-within-a-pharmacist-clinic
#1
Elizabeth K Pogge, Lindsay E Davis
OBJECTIVE: The objective of this research was to describe the use of pharmacist-managed sacubitril/valsartan therapy in a multi-center, outpatient cardiac group. BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNi), is a novel agent for the treatment of heart failure. An ARNi is recommended by national guidelines to be used in place of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy for patients who remain symptomatic...
February 17, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29454503/a-mechanistic-look-at-sacubitril-valsartan-action-unravelling-magician-s-secrets
#2
EDITORIAL
Giuseppe Vergaro, Alberto Aimo, Andrea Barison, Michele Emdin
No abstract text is available yet for this article.
February 9, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29453287/adoption-of-sacubitril-valsartan-for-the-management-of-patients-with-heart-failure
#3
Lindsey R Sangaralingham, S Jeson Sangaralingham, Nilay D Shah, Xiaoxi Yao, Shannon M Dunlay
BACKGROUND: The US Food and Drug Administration approved the use of sacubitril/valsartan in patients with heart failure with reduced ejection fraction in July 2015. We aimed to assess the adoption and prescription drug costs of sacubitril/valsartan in its first 18 months after Food and Drug Administration approval. METHODS AND RESULTS: Using a large US insurance database, we identified privately insured and Medicare Advantage beneficiaries who filled a first prescription for sacubitril/valsartan between July 1, 2015, and December 31, 2016...
February 2018: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29450561/cognitive-performance-of-patients-with-chronic-heart-failure-on-sacubitril-valsartan-a-retrospective-cohort-study
#4
R De Vecchis, C Ariano, G Di Biase, M Noutsias
BACKGROUND: Sacubitril, a neprilysin inhibitor in the combination molecule sacubitril/valsartan, slows down degradation of endogenous natriuretic peptides, thereby enhancing their beneficial cardiovascular effects. However, sacubitril might also promote neuronal dysfunction and cognitive impairment in patients with chronic heart failure (CHF) treated with sacubitril/valsartan, due to possible neprilysin inhibition at the level of Central Nervous System. METHODS: A retrospective cohort study was undertaken to detect the effects exerted by sacubitril/valsartan on cognitive function in CHF patients...
February 15, 2018: Herz
https://www.readbyqxmd.com/read/29446691/early-insights-into-the-characteristics-and-evolution-of-clinical-parameters-in-a-cohort-of-patients-prescribed-sacubitril-valsartan-in-germany
#5
Rolf Wachter, Daniel Viriato, Sven Klebs, Stefanie S Grunow, Matthias Schindler, Johanna Engelhard, Catia C Proenca, Frederico Calado, Raymond Schlienger, Markus Dworak, Bogdan Balas, Sara Bruce Wirta
OBJECTIVES: This study aimed to provide early insights into sacubitril/valsartan (sac/val) prescription patterns and the demographic and clinical characteristics of patients prescribed sac/val in primary care and cardiology settings in Germany. METHODS: The study used electronic medical records from the German IMS® Disease Analyzer database. Patients with ≥1 prescription for sac/val during 1 January-31 December 2016 (n = 1643) were identified and followed up for ≤12 months from first prescription...
February 15, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29432709/neprilysin-inhibition-and-endothelin-1-elevation-focus-on-the-kidney
#6
Lodi C W Roksnoer, Estrellita Uijl, René de Vries, Ingrid M Garrelds, A H Jan Danser
Increasing the degree of renin-angiotensin system (RAS) blockade by combining ≥2 RAS blockers marginally increases efficacy, but results in more side effects. Hence, interference with other systems is currently being investigated, like potentiation of natriuretic peptides with neprilysin inhibitors. However, the neprilysin inhibitor thiorphan was recently found to increase endothelin-1 when administered to TGR(mREN2)27 (Ren2) rats on top of RAS blockade. Here we investigated whether this effect is thiorphan-specific, by comparing the neprilysin inhibitors thiorphan and sacubitril, administered by osmotic minipumps at a low or high dose for 7 days, in Ren2 rats...
February 9, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29431251/effect-of-sacubitril-valsartan-on-recurrent-events-in-the-prospective-comparison-of-arni-with-acei-to-determine-impact-on-global-mortality-and-morbidity-in-heart-failure-trial-paradigm-hf
#7
Ulrik M Mogensen, Jianjian Gong, Pardeep S Jhund, Li Shen, Lars Køber, Akshay S Desai, Martin P Lefkowitz, Milton Packer, Jean L Rouleau, Scott D Solomon, Brian L Claggett, Karl Swedberg, Michael R Zile, Guenther Mueller-Velten, John J V McMurray
AIMS: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs. enalapril on recurrent events, incorporating all HF hospitalizations and cardiovascular (CV) deaths in PARADIGM-HF, using a variety of statistical approaches advocated for this type of analysis. METHODS AND RESULTS: In PARADIGM-HF, a total of 8399 patients were randomized and followed for a median of 27 months...
February 12, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29411335/evolving-role-of-natriuretic-peptides-from-diagnostic-tool-to-therapeutic-modality
#8
Ines Pagel-Langenickel
Natriuretic peptides (NP) are widely recognized as key regulators of blood pressure, water and salt homeostasis. In addition, they play a critical role in physiological cardiac growth and mediate a variety of biological effects including antiproliferative and anti-inflammatory effects in other organs and tissues. The cardiac release of NPs ANP and BNP represents an important compensatory mechanism during acute and chronic cardiac overload and during the pathogenesis of heart failure where their actions counteract the sustained activation of renin-angiotensin-aldosterone and other neurohormonal systems...
February 7, 2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29402859/ventricular-arrhythmic-storm-after-initiating-sacubitril-valsartan
#9
Lourdes Vicent, Miriam Juárez, Irene Martín, Jorge García, Hugo González-Saldívar, Vanesa Bruña, Carolina Devesa, Iago Sousa-Casasnovas, Francisco Fernández-Avilés, Manuel Martínez-Sellés
OBJECTIVES: Sacubitril/valsartan was approved recently for the treatment of patients with heart failure and reduced ejection fraction. We present 6 cases of ventricular arrhythmia, that occurred shortly after sacubitril/valsartan initiation, that required drug withdrawal. Other potential triggering factors of electrical storm were ruled out and, from the arrhythmic perspective, all of the patients were stable in the previous year. Our aim is to describe the possible association of sacubitril/valsartan with arrhythmic storm...
January 16, 2018: Cardiology
https://www.readbyqxmd.com/read/29398176/profound-vasoplegia-during-sacubitril-valsartan-treatment-after-heart-transplantation
#10
Aws Almufleh, Lisa M Mielniczuk, Radoslav Zinoviev, Andrew Moeller, Ross A Davies, Ellamae Stadnick, Vincent Chan, Sharon Chih
Vasoplegia occurs in up to 16% of patients who undergo heart transplantation (HT) and is associated with significant morbidity and mortality. We present a case of a 61-year-old man with ischemic cardiomyopathy receiving sacubitril/valsartan (Entresto; Novartis, Cambridge, MA) who developed profound hypotension after HT. He was treated with intravenous methylene blue and high-dose vasopressors, but developed acute kidney injury requiring dialysis and a prolonged stay in the intensive care unit. This case supports a potent vasodilatory effect of sacubitril/valsartan, and if confirmed by other studies, might warrant consideration for withholding treatment while awaiting HT, particularly in patients with risk factors for vasoplegia...
December 11, 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29375230/prolonged-first-dose-hypotension-induced-by-sacubitril-valsartan
#11
Fu-Chih Hsiao, Pao-Hsien Chu
Entresto was recommanded by major guidelines as the frontline therapy for heart failure with reduced ejection fraction since its clinical benefit was proved by the PARADIGM-HF trial. Angiotensin converting enzyme inhibitors are the cornerstone of the treatment of HF. Varying incidences of first-dose hypotension have been reported and recognized as a potential limiting factor for prescribing. According to previous reports, the onset of hypotension mostly occur 3-5 hours after the first dose. However, the pattern of entresto-related hypotension has not been reported...
January 2018: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/29374807/the-sacubitril-valsartan-a-first-in-class-angiotensin-receptor-neprilysin-inhibitor-arni-potential-uses-in-hypertension-heart-failure-and-beyond
#12
REVIEW
Kazuomi Kario
PURPOSE OF REVIEW: Sacubitril/valsartan (LCZ696) is a first-in-class, novel-acting, angiotensin receptor neprilysin inhibitor (ARNI) that provides inhibition of neprilysin and the angiotensin (AT 1 ) receptor. A recent clinical trial PRARDIGM-HF demonstrated that this drug is superior to angiotensin-converting enzyme (ACE) inhibitors for improving the prognosis in the patients with heart failure, and this has resulted in the drug being included in clinical practice guidelines for the management of heart failure with reduced ejection fraction (EF)...
January 27, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29369824/was-the-enalapril-dose-too-low-in-the-paradigm-hf-trial
#13
Sabrina Bernardez-Pereira, Felix José Alvares Ramires, Rachel Figueiredo Tavares de Melo, Antonio Carlos Pereira-Barretto
Heart failure (HF) is a common clinical syndrome associated with significant morbidity and mortality, and there remains a clear need for innovative therapies that can modify disease progression. Sacubitril/valsartan (LCZ696) is a novel complex that combines simultaneous neprilysin inhibition and angiotensin II receptor blockade, that has demonstrated significant cardiovascular death or HF hospitalization reduction in the Prospective Comparison of Angiotensin Receptor/Neprilysin Inhibitor (ARNI) with Angiotensin-Converting Enzyme (ACE) Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial when compared to evidence-based doses of the gold-standard ACE inhibitor enalapril...
January 24, 2018: Cardiology in Review
https://www.readbyqxmd.com/read/29352367/continuous-manufacturing-of-co-crystals-challenges-and-prospects
#14
REVIEW
Rahul B Chavan, Rajesh Thipparaboina, Balvant Yadav, Nalini R Shastri
The last decade has witnessed extensive growth in the field of co-crystallization for mitigating the solubility and dissolution-related issues of poorly soluble drugs. This is largely because co-crystals can modify the physicochemical properties of drugs without any covalent modification in the drug molecules. The US Food and Drug Administration (FDA) now considers drug products that are designed to contain a new co-crystal, analogous to new polymorph of the active pharmaceutical ingredient (API). This positive change in regulatory perspective coupled with successful commercialization of valsartan-sacubitril co-crystal (Entresto, Novartis) has now brought co-crystals into focus, in both industries as well as academia...
January 19, 2018: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/29350254/sacubitril-valsartan-for-heart-failure-with-reduced-left-ventricular-ejection-fraction-a%C3%A2-retrospective-cohort-study
#15
R De Vecchis, C Ariano, G Di Biase, M Noutsias
BACKGROUND: The combination drug sacubitril/valsartan was reported to be superior to enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) hospitalizations in patients with cardiac insufficiency and reduced left ventricular ejection fraction (HFREF) with NYHA class II-IV. METHODS: Our retrospective cohort study aimed to assess the effects of sacubitril/valsartan in addition to a beta-blocker and mineral receptor antagonist (MRA) in a group of HFREF patients with NYHA class II-III HF vs...
January 19, 2018: Herz
https://www.readbyqxmd.com/read/29345425/eligibility-of-sacubitril-valsartan-in-a-real-world-heart-failure-population-a-community-based-single-centre-study
#16
Helena Norberg, Ellinor Bergdahl, Krister Lindmark
AIMS: This study aims to investigate the eligibility of the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study to a real-world heart failure population. METHODS AND RESULTS: Medical records of all heart failure patients living within the catchment area of Umeå University Hospital were reviewed. This district consists of around 150 000 people...
January 18, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29338113/efficacy-and-safety-of-sacubitril-valsartan-in-patients-with-essential-hypertension-uncontrolled-by-olmesartan-a-randomized-double-blind-8-week-study
#17
Deanna G Cheung, Diego Aizenberg, Vladimir Gorbunov, Kudsia Hafeez, Chien-Wei Chen, Jack Zhang
A majority of patients with hypertension fail to achieve blood pressure (BP) control despite treatment with commonly prescribed drugs. This randomized, double-blind phase III trial assessed the superiority of sacubitril/valsartan 200 mg (97/103 mg) to continued olmesartan 20 mg in reducing ambulatory systolic BP after 8-week treatment in patients with mild to moderate essential hypertension uncontrolled with olmesartan 20 mg alone. A total of 376 patients were randomized to receive either sacubitril/valsartan (n = 188) or olmesartan (n = 188)...
January 16, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29338112/benefits-and-pitfalls-of-sacubitril-valsartan-treatment-in-patients-with-hypertension
#18
Steven G Chrysant
No abstract text is available yet for this article.
January 16, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29327807/uric-acid-is-important-but-there-is-something-that-matters-even-more-to-deliver-sacubitril-valsartan-to-eligible-heart-failure-patients
#19
EDITORIAL
Maria Rosa Costanzo
No abstract text is available yet for this article.
January 12, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29325796/lcz696-sacubitril-valsartan-an-angiotensin-receptor-neprilysin-inhibitor-attenuates-cardiac-hypertrophy-fibrosis-and-vasculopathy-in-a-rat-model-of-chronic-kidney-disease
#20
Yasunori Suematsu, Wanghui Jing, Ane Nunes, Moti L Kashyap, Mahyar Khazaeli, Nosratola D Vaziri, Hamid Moradi
BACKGROUND: Chronic kidney disease (CKD) is associated with cardiac hypertrophy, fibrosis and increased risk of cardiovascular mortality. LCZ696 (Sacubitril/valsartan) is a promising agent which has shown significant potential in treatment of heart failure. We hypothesized that LCZ696 is more effective than valsartan alone in treatment of cardiovascular abnormalities associated with experimental CKD. METHODS AND RESULTS: Male Sprague Dawley rats underwent 5/6 nephrectomy and were subsequently randomized to no treatment (CKD), 30 mg/kg valsartan (VAL), or 60 mg/kg LCZ696 (LCZ)...
January 8, 2018: Journal of Cardiac Failure
keyword
keyword
71365
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"